Kenneth d’Entremont
Vermögen: 5 Mio $ am 30.06.2026
Vermögen: 5 Mio $ am 30.06.2026
Mr. Kenneth d’Entremont is a Chief Executive Officer & Director at Medexus Pharmaceuticals, Inc. He is on the Board of Directors at Medexus Pharmaceuticals, Inc. Mr. d’Entremont was previously employed as a President, Chief Executive Officer & Director by Medexus, Inc. and a General Manager & VP-Business Development by Sanofi Canada, Inc. He received his undergraduate degree from McMaster University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.12.2025 | 1.504.807 ( 4,75 % ) | 5 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MEDEXUS PHARMACEUTICALS INC. | Vorstandsvorsitzender | 17.12.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
Medexus, Inc.
Medexus, Inc. Drugstore ChainsRetail Trade Engages in licensing, registration, marketing, sales and distribution of pharmaceutical products | Gründer | 17.12.2018 |
Sanofi Canada, Inc.
Sanofi Canada, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and distributes pharmaceutical products | Corporate Officer/Principal | 01.01.1999 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
McMaster University
McMaster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medexus Pharmaceuticals, Inc.
Medexus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides healthcare products which focuses on therapeutic areas of auto-immune disease and pediatrics | Health Technology |
Sanofi Canada, Inc.
Sanofi Canada, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops, manufactures and distributes pharmaceutical products | Health Technology |
Medexus, Inc.
Medexus, Inc. Drugstore ChainsRetail Trade Engages in licensing, registration, marketing, sales and distribution of pharmaceutical products | Retail Trade |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen